Zhejiang Huahai Pharmaceutical Co (SHSE:600521) FFO


SHSE:600521 Zhejiang Huahai Pharmaceutical Co Ltd SHSE:600521
82 GF Score
Price ¥16.26
GF Value ¥16.38
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Zhejiang Huahai Pharmaceutical Co FFO?

FFO (Funds from operations) only applies to REITs.

SHSE:600521
82GF Score
Zhejiang Huahai Pharmaceutical Co Ltd SHSE:600521
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Huahai Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥16.26 is trading 0.7% below its estimated GF Value™ of ¥16.38. GuruFocus considers Zhejiang Huahai Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:600521:

  • FFO:
  • GF Value™: ¥16.38 vs. price of ¥16.26 (0.7% below fair value)
  • GF Score™: 82/100 with 8 warning signs

No single metric tells the full story. See the SHSE:600521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zhejiang Huahai Pharmaceutical Co Business Description

Address Xunqiao, Zhejiang Province, Linhai, CHN, 317024
Zhejiang Huahai Pharmaceutical Co Ltd is engaged in research and development, production, and sales of multi-dosage preparations, biological drugs, innovative drugs, and specialty APIs. The company's products include irbesartan hydrochlorothiazide tablets, losartan potassium tablets, paroxetine hydrochloride tablets, sertraline hydrochloride tablets, linagliptin tablets, dabigatran etexilate capsules, pemetrexed disodium for injection, esomeprazole magnesium enteric-coated capsules, torsemide injection, and others.
82GF Score

Get the complete analysis for SHSE:600521

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥16.26
Price
¥16.38
GF Value